Effect of side effects antituberculosis preparations on upshots of the treatment patients with multidrug-resistant tuberculosis, who had received treatment on scheme of the program DOTS-PLUS
https://doi.org/10.20538/1682-0363-2011-1-132-136
Abstract
At treatment of patients with multidrug-resistant tuberculosis of lungs on scheme of the program DOTS-PLUS was noted development that or other side reaction on the part of organs and systems. We studied temper, frequency of the development of side effect upon upshot of the treatment beside by 101 patients in process of stationary course of the treatment.
About the Authors
D. Yu. Schegertsov
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
Ye. V. Nekrasov
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
G. V. Yanova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
O. V. Filinyuk
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
L. N. Buinova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
O. V. Anastasov
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
Ye. P. Stepanova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
I. G. Felker
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
References
1. Диагностика, химиотерапия, хирургия лекарственно- устойчивого туберкулеза органов дыхания: практическое руководство / под ред. А.К. Стрелиса, А.А. Стрелиса. Томск: Красное знамя, 2007. 256 с.
2. Ломакин А.В. Фармакоэкономические исследования лекарственно-устойчивого туберкулеза // Развитие фармакоэкономики и фармакоэпидемиологии в Российской Федерации: материалы конгр. с междунар. участием. М., 2008. С. 47—48.
3. Iseman M.D. MDR-TB and the developing world — a problem no longer to be ignored: the WHD announces «DOTSPLUS» strategy // Int. J. Tuberc. Lung Dis. 1998. № 2 (11). P. 867.
4. Kim J.W., Mukherju J.S., Rich M.L. et al. From multidrugresistent tuberculosis DOTS expansion and beyond: making the most of a paradigm shift // Tuberculosis. 2003. № 83 (1—3). P. 59—65.
5. Leimane V., Riekstina V., Holtz T. et al. Clinical outcome of individualized treatment of multidrug-resistent tuberculosis in Latvia: a retrospective cohort study // The Luncet. 22 Jan. 2005. V. 365, issue 9456. P. 318—326.
6. Marcos A. Espinal, Dr. PH. Sang Jac Kim, Pedro J. Suar et al. Standart Short-Course Chemotherapy for Drug-Resistant Tuberculosis Treatment Outcomes in 6 Countries // JAMA. 2000. V. 283, № 19. P. 2537—2545.
7. Mitnick C.D., Bayona J., Palacios E. et al Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru // New England Journal of Medicine. 2003. 348. P. 1219— 1228.
Review
For citations:
Schegertsov D.Yu., Nekrasov Ye.V., Yanova G.V., Filinyuk O.V., Buinova L.N., Anastasov O.V., Stepanova Ye.P., Felker I.G. Effect of side effects antituberculosis preparations on upshots of the treatment patients with multidrug-resistant tuberculosis, who had received treatment on scheme of the program DOTS-PLUS. Bulletin of Siberian Medicine. 2011;10(1):132-136. (In Russ.) https://doi.org/10.20538/1682-0363-2011-1-132-136
Views:
616
Email this article 